Antiviral treatment of viral hepatitis C in patients with HIV infection
Keywords:
ART, HAART, HIV, HCVAbstract
Hepatitis C virus diseases are now widespread among HIVinfected patients. Before highly active antiretroviral therapy (HAART) , late complications of chronic liver disease caused by HCV infection were rare, as patients died from the effects of severe HIV/AIDS-induced immunodeficiency. The widespread introduction of antiviral treatment (ART) has significantly reduced morbidity and mortality in HIV-infected patients and, as a result, complications of liver disease due to chronic HCV infection are now emerging. The simultaneous presence of two or more infections (HIV infection and viral hepatitis C) increases the risk of HCV transmission, complicates the management of these patients and increases the costs of care and treatment. A retrospective, cross-sectional study was conducted in the period 2017-2021 at the IMSP Clinical Hospital of Infectious Diseases “T.Ciorba”, Chisinau. In the study we evaluated the medical records of patients with HIV-HCV co-infection undergoing ART between 2017 and 2021. Coinfection with HIV and HCV viruses alters the epidemiology, clinical, virological and natural course of hepatitis C, as a result of which it manifests differently and requires different approaches to its detection, diagnosis and management. All patients with HIV infection should be screened for HCV. Patients co-infected with HIV and HCV are more difficult to treat than mono-infected patients. Treatment of HCV infection in co-infected patients should be initiated earlier in the course of both HIV and HCV infection.
References
1. Cooke G. S., Andrieux-Meyer I., Applegate T. L. et al. Lancet Gastroenterology&Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology&Hepatology Commission Lancet Gastroenterol Hepatol. 2019;4:135184. https://doi.org/10.1016/S2468-1253(18)30412-6
2. Chung R. Management of HIV/HCV coinfection. The PRN Notebook. 2004;9(1):14.
3. Gatti F., Nasta P., Matti A., Manno D., Mendeni M., Pouto M. Treating hepatitis C virus in HIV patients: are side effects a real obstacle? AIDS Rev. 2007;9:16-24.
4. Martin-Carbonero L., Soriano V., Valencia E. et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses.2001;17(16):1467-71. https://doi.org/10.1089/08892220152644160
5. Platt L., Easterbrook P., Gower E. et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797-808. https://doi.org/10.1016/S1473-3099(15)00485-5
6. Sugimoto K., Stadanlick J., Ikeda F. et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellularimmuneresponse. Hepatology.2003;37(3) :590 https://doi.org/10.1053/jhep.2003.50103. Google Scholar Crossref PubMed. https://doi.org/10.1053/jhep.2003.50103
7. Taylor L. E., Swan T., Mayer K. H. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012;55(Suppl 1):S33-42. https://doi.org/10.1093/cid/cis367. Google ScholarCrossref PubMed. https://doi.org/10.1093/cid/cis367
8. Thomas D. L. HIV/HCV coinfection: comorbidity and clinical implications. Adv Stud Med. 2005;5:S352-5.
9. Thomas D. L. Global Elimination of Chronic Hepatitis. N Engl J Med. 2019;380:2041-2050. https://doi.org/10.1056/NEJMra1810477
10. Trickey A., Fraser H., Lim A. G. et.al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4:435-444. https://doi.org/10.1016/S2468-1253(19)30085-8
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
